Circulate Health

Thesis

Circulate Health raised a $12M seed round from Khosla Ventures to develop therapeutic plasma exchange (TPE) technology. Plasma exchange involves removing a patient's blood plasma and replacing it with donor plasma or albumin solution, and has shown promising results in age-related conditions based on seminal research from Stanford and UC Berkeley demonstrating that young blood plasma can rejuvenate aged tissues. Khosla Ventures' backing is significant. The firm has a strong track record in health-tech investments and its founder Vinod Khosla has been publicly bullish on longevity science. The $12M seed is appropriately sized for a medical device/therapeutic procedure company at this stage, providing runway for clinical development and regulatory preparation. Therapeutic plasma exchange is already FDA-approved for certain conditions (autoimmune disorders, neurological conditions), which provides a regulatory framework that pure longevity interventions lack. Circulate Health could potentially pursue indications where TPE is already established while building evidence for age-related applications. A 'Trojan horse' strategy that de-risks the regulatory pathway. The company is early-stage with limited public information beyond the seed round details. As a private company, access is restricted to accredited investors. The key question is whether Circulate Health can demonstrate clinical efficacy in age-related indications beyond the existing TPE evidence base, and whether the economics of plasma exchange can scale to a consumer longevity market.

Catalysts

• +Khosla Ventures network could drive strategic partnerships with hospital systems and health-tech companies
• +FDA-approved TPE for existing indications provides regulatory precedent for expanded applications
• +Stanford/UC Berkeley young blood plasma research creating scientific validation for the approach

Risks

• -Very early stage with limited public information beyond seed round disclosure
• -Therapeutic plasma exchange requires clinical infrastructure that is expensive to scale
• -Longevity applications of TPE are unproven beyond animal models and small-scale human studies

Common questions